Company: BIVIW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001520138-25-000343
Chunk: 14

Company: BIOVIE INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
 computation of diluted net loss per
share attributable to common stockholders because including them would have had an anti-dilutive effect:

    Schedule of dilutive securities were excluded from the computation of diluted loss per share 

    September 30, 2025  
    September 30, 2024 

    Number of Shares  
    Number of Shares 
  
    Stock Options 
     84,872  
     51,800 
  
    Warrants 
     8,307,038  
     431,600 
  
    Restricted Stock Units 
     5,457  
     3,457 
  
    Notes payable conversion option 
     -  
     3,582 

     8,397,367  
     490,439 

    11

Grant program

The Company records expenses related to the DOD
Long Covid Program as such expenses are incurred. The reimbursement of such expenses is recognized upon receipt of the reimbursement,
or when it is probable the reimbursement will be received, as a credit against the respective expense account.

Segment Reporting

The Company operates as one operating segment
with a focus on its efforts to develop drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver
disease. The Company's Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources
to the operations of the Company based on the line items included within these financial statements. This enables the CEO to assess the
overall level of available resources and determine how best to deploy these resources across functions, clinical trials, and development
projects in line with the long-term company-wide strategic goals. 

    12

4.Intangible Assets

The Company’s intangible assets consist of intellectual property
acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives.

The following is a summary of the Company’s intangible assets:

    Schedule of intangible assets 

    September 30, 2025  
    June 30, 2025 

    Intellectual Property 
    $2,293,770  
    $2,293,770 
  
    Less: Accumulated Amortization 
     (2,172,773) 
     (2,115,429)
  
    Intellectual Property, net 
    $120,997  
    $178,341 

Amortization expense was $57,344 in each of the